Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Unprecedented advances have been made in the treatment of cancer through the use of antibody against immune checkpoints, priming immune system instead of targeting cancer, with approval of several antibodies for multiple cancer types. However, so far we are merely seeing the tip of the iceberg because responses to this form of therapy are not universal. Next-generation antibody drug is needed. TIM-3 negatively regulates immune system and is one of the next generation targets. We have generated 13 clones of TIM-3 antibodies, potentially can be anti-tumor drug. Here, a serial of experiments in biochemical, cellular, and animal models experiments are proposed. Evolution of this understanding will ultimately help guide treatment strategies to enhance therapeutic responses.
Yuzhuo Wang
Charlene Hoi-Broad
Applied Biological Materials
Medicine
Medical devices
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.